Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
2011-07-19
2011-07-19
Kemmerer, Elizabeth C. (Department: 1649)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
C424S139100, C424S158100, C424S141100
Reexamination Certificate
active
07981415
ABSTRACT:
The present application relates to compositions of humanized anti-PAI-1 antibodies and antigen-binding fragments thereof which convert PAI-1 to its latent form. One aspect relates to antibodies having one or more modifications in at least one amino acid residue of at least one of the framework regions of the variable heavy chain, the variable light chain or both. Another aspect relates to antibodies which bind and neutralize PAI-1 by converting PAI-1 to its latent form or increasing proteolytic cleavage. Another aspect relates to the use of humanized antibodies which inhibit or neutralize PAI-1 for the detection, diagnosis or treatment of a disease or condition associated with PAI-1 or a combination thereof.
REFERENCES:
patent: 5422245 (1995-06-01), Nielsen et al.
patent: 6767540 (2004-07-01), Oh et al.
patent: 7592429 (2009-09-01), Paszty et al.
patent: 2001/0034327 (2001-10-01), Brunner et al.
patent: 2003/0096733 (2003-05-01), Ny et al.
patent: 2003/0217371 (2003-11-01), Vaughan et al.
patent: 2005/0037956 (2005-02-01), Hanashiro et al.
patent: 2006/0058369 (2006-03-01), Vaughan et al.
patent: 2007/0048315 (2007-03-01), Presta
patent: WO 00/45771 (2000-08-01), None
patent: WO-2006-113909 (2006-10-01), None
Agren, A. et al., “Evaluation of low PAI-1 activity as a risk factor for hemorrhagic diathesis,” J. Thrombosis Haemostasis 4:201-208 (2005).
Al-Batran, S. et al., “Three-Dimensional In Vitro Cocultivation of Lung Carcinoma Cells with Human Bronchial Organ Culture as a Model for Bronchial Carcinoma,” Am. J. Resp. Cell Mol. Biol. 21:200-208 (1999).
Alessi, Marie-Christine, et al., “PAI-1 and the Metabolic Syndrome: Links, Causes and Consequences,” Am Heart Assoc: Arterioscler. Thromb. Vasc. Biol. 26:2200-2207 (2006).
Berry, C.N. et al., “Antithrombotic Activity of a Monoclonal Antibody Inducing the Substrate form of Plasminogen Activator Inhibitor Type 1 in Rat Models of Venous and Arterial Thrombosis,” British J of Pharmacology 125:29-34 (1998).
Britton, R. C. et al., “Intrahepatic Veno-Occlusive Disease in Cirrhosis with Chronic Ascites: Diagnosis by Hepatic Phlebography and Results of Surgical Treatment,” Anals of Surgery 158(3):370-382 (1963).
Correia, Marcello L.G. et al., “A Role for Plasminogen Activator Inhibitor-1 Obesity: From Pie to PAI?” Am Heart Assoc: Arterioscler. Thromb. Vasc. Biol. 26:2183-2185 (2006).
“Correspondence to the Editor,” Blood Journal 102:7: 2695-2696 (2003).
Dai, Erbin, et al., “Serp-1, a Viral Anti-Inflammatory Serpin Regulates Cellular Serine Proteinase and Serpin Responses to Vascular Injury,” J Bio Chem 278:20:18563-18572 (2003).
DeBrock, S. and Declerck, P.J., “Neutralization of plasminogen activator inhibitor-1 inhibitory properties: identification of two different mechanisms,” Biochimica Biophysica Acta 1337:257-266 (1997).
Declerck, P.J. et al., “Measurement of Plasminogen Activator Inhibitor 1 in Biologic Fluids with a Murine Monoclonal Antibody-Based Enzyme-Linked Immunosorbent Assay,” Blood Journal 71:1:220-225 (1988).
Downer, G. et al., “Analysis of Renal Fibrosis in a Rabbit Model of Crescentic Nephritis,” J. Clin. Invest. 82:998-1006 (1988).
Eddy, Allison A. et al., “Plasminogen Activator Inhibitor-1 in Chronic Kidney Disease: Evidence and Mechanisms of Action,” J Am Soc Nephrol 17:2999-3012 (2006).
Fried, M.W. et al., “Post-Transplant Complications Serum Hyaluronic Acid in Patients with Veno-Occlusive Disease Following Bone Marrow Transplant” Bone Marrow Transp. 27:635-639 (2001).
Hemingway, Harry et al. “Prevalence of Angina in Women Versus Men: a Systematic Review and Meta-Analysis of International Variations Across 31 Countries,” J Am Heart Assoc, Circulation 117:1526-1536 (2008).
Hicks, K.O. et al., “Use of Three-Dimensional Tissue Cultures to Model Extravascular Transport and Predict In Vivo Activity of Hypoxia-Targeted Anticancer Drugs,” J. National Cancer Institute 98(16):1118-1128 (2006).
Holdsworth, S.R. et al., “Abrogation of Macrophage-dependent Injury in Experimental Glomerulonephritis in the Rabbit,” J. Clin. Invest. 68:686-698 (1981).
Iredale, J.P., “Models of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ,” J. Clin. Investig. 117(3):539-548 (2007).
Kalady, M.F. et al., “Decreased Fibrinolytic Activity in Porcine-to-Primate Cardiac Xenotransplantation,” Mol. Med. 4:629-637 (1998).
Kim, J.B. et al., “Three-dimensional in vitro tissue culture models of breast cancer—a review,” Breast Cancer Res. Treat. 85(3):281-291 (2004).
King, D.J. et al., “Expression, purification and characterization of a mouse-human chimeric antibody and chimeric Fab' fragment,” Biochem. J. 281:317-323 (1992).
Lee, J-H, et al. “Veno-Occlusive Disease of the Liver After Allogenic Bone Marrow Transplantation for Severe Aplastic Anemia” Bone Marrow Transp. 26:657-662 (2000).
Liang, X. et al., “Plasminogen activator inhibitor-1 modules adipocyte differentiation,” Am. J. Physiol. Endocrinol. Metab. 290(1):E103-E-113 (2006).
Sugimoto, H. et al., “Renal Fibrosis and Glomerulosclerosis in a New Mouse Model of Diabetic Nephropathy and Its Regression by Bone Morphogenic Protein-7 and Advanced Glycation End Product Inhibitors,” Diabetes 56:1825-1833 (2007).
Tucker, H.M. et al., “Tissue Plasminogen Activator Requires Plasminogen to Modulate Amyloid-β Neurotoxicity and Deposition,” J. Neurochem. 2172-2177 (2000).
Tucker, H.M. et al., “The Plasmin System Is Induced by and Degrades Amyloid-β Aggregates,” J. Neuroscience 20(11):3937-3946 (2000).
Vincan, E. et al., “A Human Three-Dimensional Cell Line Model Allows the Study of Dynamic and Reversible Epithelial-Mesenchymal and Mesenchymal-Epithelial Transition That Underpins Colorectal Carcinogenesis,” Cells Tissues Organs 185:20-28 (2007).
Wang, D. et al., “β-Amyloid Degradation and Alzheimer's Disease,” J. Biomedicine Biotech. vol. 2006, Article ID 58406, pp. 1-12, (2006).
PCT/US08/75489 Search Report dated Feb. 12, 2009.
Staunton Donald E.
Vasquez Maximiliano
Ballard Kimberly A.
Cisthera, Inc.
Kemmerer Elizabeth C.
Wilson Sonsini Goodrich & Rosati
LandOfFree
Humanized PAI-1 antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Humanized PAI-1 antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Humanized PAI-1 antibodies will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2632856